Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BeiGene, Ltd.
Accounting for nearly a third of the global clinical pipeline, the oncology sector is set to grow to $250bn in sales by 2024 predicts a new report, identifying five research trends driving broad changes. COVID-19 has impacted trials, with 2% having been slowed down, suspended or discontinued.
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.
Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.
- In Vitro Diagnostics
Drug Discovery Tools
- Other Names / Subsidiaries
- MapKure, LLC